KNSA NASDAQ
Kiniksa Pharmaceuticals International, plc
1W: -8.2%
1M: -2.8%
3M: -8.1%
YTD: +73.7%
1Y: +88.2%
3Y: +361.3%
5Y: +582.7%
$89.20
+16.22 (+22.23%)
After Hours: $89.50 (+0.30, +0.34%)
Weekly Expected Move ±4.7%
$70
$73
$77
$80
$84
Credit Risk of going bust: lower than 91% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down more than 99.9%), Kiniksa Pharmaceuticals International, plc would be worth roughly what it owes.
Total debt $8.9M against a stock market value of $5.69B.
Distance to default 14.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.4M (short-term plus half of long-term), stock volatility 47.9%; Altman Z'' 5.80. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $8.9M against a stock market value of $5.69B.
Distance to default 14.80 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.4M (short-term plus half of long-term), stock volatility 47.9%; Altman Z'' 5.80. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-02-22
Earliest Filing
2024-06-25
Latest Filing
supplier: 1
partner: 1
Counterparties (Filed by KNSA)
2 relationshipsCompanies named in KNSA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Samsung Biologics Co., Ltd. | — | supplier | Agreement for technology transfer, process performance qualification, manufacturing, and supply of ARCALYST drug substan | 2024-06-25 | View |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | — | partner | Exclusive collaboration and license agreement for rilonacept and mavrilimumab in specified Asian territories. | 2022-02-22 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-27 | Earnings Release; Exhibits | View | |
| 2026-10-22 | Officer/Director Change | View | |
| 2026-07-28 | Earnings Release; Exhibits | View | |
| 2026-05-29 | Shareholder Vote | View | |
| 2026-05-26 | Material Agreement; Exhibits | Agreement | View |
| 2026-05-01 | Officer/Director Change | View | |
| 2026-04-28 | Earnings Release; Exhibits | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-14 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-28 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-03 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-07-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-05 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-03 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-04-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-23 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-02-25 | Termination of Material Definitive Agreement; Results of Operations and Financial Condition; Costs A | View | |
| 2025-01-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR